AR and Familial prostate cancer: Within efforts to develop degraders for the androgen receptor (AR) in metastatic castration-resistant prostate cancer, and to improve their cellular potency compared to previously reported AR degraders, such as ARCC-4 (Table 1),120 the Wong group identified the methylated benzylic position at the RHS of VHL inhibitors as attractive tethering point for linker attachment.94